Skip to main content

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

  • Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ET
  • Jefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT

A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednesday, November 13, 2024.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  224.76
+3.49 (1.58%)
AAPL  267.80
-4.04 (-1.49%)
AMD  204.28
+6.17 (3.12%)
BAC  54.94
+0.39 (0.71%)
GOOG  302.01
+3.95 (1.33%)
META  658.70
+9.20 (1.42%)
MSFT  480.24
+4.12 (0.87%)
NVDA  172.20
+1.26 (0.74%)
ORCL  184.28
+5.82 (3.26%)
TSLA  475.08
+7.82 (1.67%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.